Space Travel News  
EPIDEMICS
Chinese president calls latest pharma scare "vile"
by Staff Writers
Shanghai (AFP) July 23, 2018

Chinese President Xi Jinping on Monday described a vaccine safety scandal as "vile" and "shocking" as police opened a criminal investigation into the firm responsible and its management.

Xi, on a trip to Africa, echoed the calls from Premier Li Keqiang for a thorough investigation and stern action over the latest safety scare to hit the pharmaceutical industry.

"Changchun Changsheng Biotechnology's illegal production of vaccines is vile in nature and shocking," Xi said, according to state broadcaster CCTV.

The mounting scandal stemming from a sub-standard rabies vaccine has raised questions about the safety of China's entire vaccine industry and sent drug company shares tumbling on Monday.

The China Food and Drug Administration announced late Sunday that it had ordered all production stopped at Changchun Changsheng, a subsidiary of one of the country's largest vaccine makers.

Police in the northeastern city of Changchun, where the company is based, said on social media they had opened a criminal investigation into illegal production of the rabies vaccine and taken the company chairwoman and four subordinates in for investigation.

Premier Li said the latest case had crossed a "line of human ethics" and vowed harsh consequences for any infractions or lax supervision.

"(We) must resolutely strike with heavy blows all law-breaking criminal behaviour, severely punish the criminals according to the law, and hold accountable those who were negligent in supervision," Li said in a website statement late Sunday.

Regulators said last week they had halted production of the rabies vaccine after finding fabricated records and other problems during an inspection.

The China Food and Drug Administration said last week the problematic rabies vaccine had not left Changsheng's factory, but the company admitted it had shipped a separate sub-standard vaccine.

- Failed standards -

That vaccine for diphtheria, tetanus and pertussis was found by regulators to fail quality standards -- but the company revealed that it had sold 250,000 doses to Shandong province last year.

Authorities in Hebei announced separately on Monday that nearly 150,000 people in the northern province received a sub-standard diphtheria, tetanus and pertussis vaccine made by another firm, Wuhan Institute of Biological Products.

Hebei said it has launched steps to administer new vaccines to those affected.

China is hit regularly by quality-control scandals, fuelling fear over the safety of food and medicines and anger at regulatory lapses.

Censors and regulators struggled to stay abreast of the public's response to the latest scandal, deleting posts on WeChat over the weekend which alleged corruption in the industry. State media battled to take control of the narrative.

Stocks of major Chinese vaccine producers plunged Monday.

In Shenzhen, Walvax Biotechnology dropped by its 10 percent daily allowable limit, as did vaccine suppliers Shenzhen Kangtai Biological Products and Chongqing Zhifei Biological Products.

After a brief trading halt, shares of Changchun Changsheng's parent company also fell by the 10 percent limit.

Concern has grown that problematic vaccines have already been administered to children.

The state-run Global Times newspaper questioned in an editorial Monday how suspect vaccines were still being produced following the harsh lessons of the past.

"People do not understand why the country had not prevented a sub-standard vaccine from being produced in the first place," it said, suggesting it may be due to "lax supervision and light punishment".


Related Links
Epidemics on Earth - Bird Flu, HIV/AIDS, Ebola


Thanks for being here;
We need your help. The SpaceDaily news network continues to grow but revenues have never been harder to maintain.

With the rise of Ad Blockers, and Facebook - our traditional revenue sources via quality network advertising continues to decline. And unlike so many other news sites, we don't have a paywall - with those annoying usernames and passwords.

Our news coverage takes time and effort to publish 365 days a year.

If you find our news sites informative and useful then please consider becoming a regular supporter or for now make a one off contribution.
SpaceDaily Contributor
$5 Billed Once


credit card or paypal
SpaceDaily Monthly Supporter
$5 Billed Monthly


paypal only


EPIDEMICS
Censors jump into action as China's latest vaccine scandal ignites
Beijing (AFP) July 22, 2018
Chinese censors on Sunday deleted articles and postings about the vaccine industry as an online outcry over the country's latest vaccine scandal intensified. Regulators said last week that they had halted production of a rabies vaccine at a large pharmaceutical company in the northeast after finding fabricated records and other problems during an inspection. It was just the latest in a series of health and safety scandals which have fuelled fear over the safety of basic food and medicine and ang ... read more

Comment using your Disqus, Facebook, Google or Twitter login.



Share this article via these popular social media networks
del.icio.usdel.icio.us DiggDigg RedditReddit GoogleGoogle

EPIDEMICS
EPIDEMICS
NASA May Have Destroyed Evidence for Organics on Mars 40 Years Ago

Seasonal 'spiders' emerge on Mars' surface

Scientists Discover "Ghost Dunes" On Mars

Airbus wins two ESA studies for Mars Sample Return mission

EPIDEMICS
Israel plans its first moon launch in December

The toxic side of the Moon

Waystation to the Solar System

Queqiao satellite the bridge to China's lunar exploration

EPIDEMICS
NASA Juno data indicate another possible volcano on Jupiter moon Io

First Global Maps of Pluto and Charon from New Horizons Published

Europa's Ocean Ascending

Jupiter's moons create uniquely patterned aurora on the gas giant planet

EPIDEMICS
Origami-inspired device helps marine biologists study aliens

Glowing bacteria on deep-sea fish shed light on evolution, 'third type' of symbiosis

Finding a Planet with a 10-Year Orbit in a Few Months

TESS Spacecraft Continues Testing Prior to First Observations

EPIDEMICS
Focus on the future of space transportation: ESA's call for ideas

Lockheed Martin to help UK Space Agency build first commercial spaceport

Indian space agency IRSO tests new engine to launch bigger payloads

Scotland chosen as site for first British space port

EPIDEMICS
China readying for space station era: Yang Liwei

China launches new space science program

China Rising as Major Space Power

China launches new-tech experiment twin satellites

EPIDEMICS
Observatories Team Up to Reveal Rare Double Asteroid

ATLAS Telescope Pinpoints Meteorite Impact Prediction

Dusk for Dawn: Mission of many firsts to gather more data in home stretch

Fragment of Impacting Asteroid Recovered in Botswana









The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us.